Centessa Pharmaceuticals (NASDAQ:CNTA) Now Covered by Chardan Capital

Chardan Capital initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a research note published on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $30.00 price objective on the stock.

A number of other brokerages have also recently commented on CNTA. Piper Sandler initiated coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They set an “overweight” rating and a $38.00 price objective on the stock. Morgan Stanley reissued an “overweight” rating and set a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $27.00.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ:CNTA opened at $12.29 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The business’s fifty day moving average price is $13.86 and its two-hundred day moving average price is $15.67. The stock has a market cap of $1.64 billion, a PE ratio of -8.03 and a beta of 1.53. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the business’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $17.17, for a total value of $120,190.00. Following the completion of the sale, the insider now owns 225,007 shares of the company’s stock, valued at $3,863,370.19. The trade was a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Iqbal J. Hussain sold 2,080 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $14.01, for a total transaction of $29,140.80. Following the completion of the transaction, the general counsel now directly owns 105,386 shares in the company, valued at approximately $1,476,457.86. This represents a 1.94 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 171,827 shares of company stock valued at $2,705,568. Corporate insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CNTA. Franklin Resources Inc. increased its holdings in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after buying an additional 1,145,823 shares during the period. JPMorgan Chase & Co. increased its stake in Centessa Pharmaceuticals by 1,969.2% in the third quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company’s stock valued at $2,173,000 after acquiring an additional 129,335 shares during the period. Geode Capital Management LLC raised its position in Centessa Pharmaceuticals by 68.7% in the third quarter. Geode Capital Management LLC now owns 56,597 shares of the company’s stock worth $905,000 after purchasing an additional 23,058 shares in the last quarter. GAMMA Investing LLC lifted its stake in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after purchasing an additional 865 shares during the period. Finally, Diadema Partners LP acquired a new stake in Centessa Pharmaceuticals during the fourth quarter valued at approximately $2,209,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.